Background. Coagulation and fibrinolysis are important in infections and systemic inflammatory response syndrome. Polymorphisms in plasminogen activator inhibitor-1 (PAI-1, SERPINE1) and tissue plasminogen activator (tPA, PLAT), such as PAI-1 (-675 4G/5G deletion/insertion) and tPA (Alu insertion/deletion [I/D]), are associated with strokes, myocardial infarctions, bacterial infections and septic shock severity, and trauma. Osteomyelitis is a mostly posttraumatic, Staphylococcal bone infection.
Coagulation and fibrinolysis play important roles in bacterial infections and systemic inflammatory response syndrome (SIRS). The fibrinolytic system counteracts the formation of vascular microthrombi through the release by endothelial cells of tissue plasminogen activator (tPA, PLAT) and plasmin. Inhibition of fibrinolysis through circulating plasminogen-activator-inhibitor (PAI-1, SERPINE1) may lead to a procoagulant state. High plasma concentrations of PAI -1 have been associated with adverse outcomes in patients with sepsis and meningococcal septic shock [1] [2] [3] . The gene coding for PAI-1 has several polymorphic loci, all leading to differences in PAI production, including a 3′ HindIII site, a CA(n) dinucleotide repeat in intron 3, and, the best studied, a 4G/5G insertion/deletion polymorphism at −675 in the promoter, which is claimed to have the most influence on PAI-1 gene expression [4] . The tPA-1 Alu (I/D) polymorphism occurs in the 8th intron of the tPA gene and consists of the presence or absence of a 311 bp Alu retrotransposon insertion. Homozygous carriers of this polymorphism have an increased "in vivo" release rate of tPA from vascular endothelial cells compared to those with other genotypes, even though this polymorphism is located in a noncoding area of the tPA gene [5] . PAI-1 and tPA genetic variants such as PAI-1 (−645 4G/5G deletion/insertion) and tPA (Alu insertion/deletion [I/D]) polymorphisms not only have been associated with clinically significant thrombotic disorders, such as strokes [6, 7] , myocardial infarction [8] [9] [10] , and infertility [11] , but also with the severity and poor prognosis of bacterial infections such as meningitis and community-acquired pneumonia [12, 13] , sepsis [2, 4, 14, 15] , and trauma [16] . Interestingly, although the PAI-1 (4G/5G) polymorphism increases the susceptibility to some bacterial infections, no infections have been associated with the tPA Alu (I/D) polymorphism except periodontitis [17] .
Osteomyelitis is a difficult-to-treat bacterial bone infection characterized by progressive inflammatory destruction of the bone, bone necrosis, and new bone formation. In adults, osteomyelitis is most often a complication of compound fractures, open surgery on a bone, or both. This infection can also develop in a noninjured bone after bacteremia, mostly in prepuberal children. In adult patients hematogenous osteomyelitis is confined to the axial skeleton. Staphylococcus aureus is the microorganism most frequently isolated in both post-traumatic and hematogenous osteomyelitis [18] .
The aim of this study was to analyze a potential association between the occurrence of osteomyelitis and polymorphisms in PAI-1 (4G/5G) and tPA Alu (I/D) and the correlation between different alleles and PA1-1/tPA complex levels.
METHODS

Patients
We enrolled 261 adult patients with a diagnosis of bacterial osteomyelitis between January 1998 and June 2012, who were admitted to the Hospital Universitario Central de Asturias (HUCA) and 3 affiliated hospitals in the same Northern Spanish region. These hospitals provide health coverage to the region of Asturias (total population of 1 million people). Patients with acute and chronic osteomyelitis were included in the study and followed for 1 year. Osteomyelitis was diagnosed using clinical and roentgenographic findings. The demonstration of bone sequestra and/or sinus tract in bone X ray, computed tomography (CT), or magnetic resonance imaging (MRI), a positive Ga 67 uptake bone scan, or a positive culture of the sequestra or sinus tract were considered diagnostic of osteomyelitis [18] . Osteomyelitis patients with no history of trauma or bone surgery, no lower limb vascular insufficiency, and without a contiguous focus of infection were considered to have hematogenous osteomyelitis. Tuberculosis and bacterial osteomyelitis in immunosuppressed patients or those receiving chemotherapy were excluded. Osteomyelitis patients receiving intravenous (IV) heparin or oral anticoagulants were also excluded from this study. Osteomyelitis was considered chronic if it was present for more than 3 months and cured if it did not relapse within a year of follow-up. Surgical and sinus tract pus samples were cultured in all of the osteomyelitis patients. Clinical and microbiologic data of the osteomyelitis patients were recorded prospectively by one of the authors (Dr Asensi) over the 14-year period of study enrolment. The DNA from these patients was stored and has been used for several gene association studies [19, 20] . In addition, 299 healthy HUCA Blood Bank donors, matched for sex and age with the osteomyelitis patients, were used as controls. All the HUCA Blood Bank donors fulfilled the basic criteria for the selection of blood donors stated by the Spanish Ministery of Health [21] . The control group was made of 205 male and 94 female donors, with a median age of 55.5 years (range, 18-65). Patients and controls were members of a homogeneous white population and were residents of the same region (Asturias, Northern Spain) that has a small foreign immigrants population (<5%). Each participant gave informed consent for the study, which was approved by the Ethics Committee of the HUCA.
Measurement of Genetic Polymorphisms of tPA and PAI
Ten mL of blood from each patient and controls were collected in a glass tube containing potassium-EDTA. Genomic DNA was extracted from peripheral leukocytes following a saltingout method and stored at −70°C until use. Insertion/deletion polymorphisms were analyzed concurrently in patients and controls by multiplex polymerase chain reaction (PCR). Results were determined by using the Peak Scanner Software v1.0 (Applied Biosystem, Foster City, CA) following capillary electrophoresis on ABI PRISM 3130 × L Genetic Analizer (Applied Biosystem, Foster City, CA). The PCR primers used for the tPA Alu (I/D) polymorphism (rs4646972) were sense 5′-GTAA GAGTTCCGTAACAGGACAGCT-3′; antisense 5′-(PET)-CC CCACCCTAGGAGAACTTCTCTTT-3′. The primers used for the PAI-1 (4G/5G) polymorphism (rs1799889) were sense 5′-CACAGAGAGAGTCTGGACACGT-3′; antisense 5′-(VIC)-CC AACAGAGGATCTTGGTCT-3′. If the insertion was present in the tPA gene, a fragment size of 421 bp was seen, whereas in the case of the deletion, a fragment size of 112 bp was observed.
For the PAI-1 gene a fragment size of 97 bp for the insertion (5G) was seen and of 96 bp for the deletion (4G). The tPA Alu (I/D) polymorphism was also genotyped individually for each osteomyelitis patient and control. Results of the PCR products for the tPA gene were then determined by fragments separation in a 3% agarose gel.
PAI-1/tPA Complex Plasma Assessment
An additional 5 mL of venous blood of each osteomyelitis patient were simultaneously drawn in a glass tube containing potassium-EDTA between 8AM and 10AM coinciding with the highest diurnal PAI-1 plasma levels, after an overnight fast and stored at −70°C until use [22] . Plasma PAI-1/tPA complex levels were simultaneously measured in the plasma of 56 osteomyelitis patients by an ELISA assay (ab108892 PAI-1/tPA Human ELISA Kit, Abcam, Cambridge, UK). Normal values of this assay range from 1.2 to 4.4 ng/mL.
Plasma Fibrinogen and D-Dimer Assessments
Plasma fibrinogen and D-Dimer were simultaneously measured in all osteomyelitis cases and controls on an IL ACL 300 
RESULTS
Clinical Characteristics of Osteomyelitis Patients
Osteomyelitis patients were mainly middle-aged men with infected bones after fractures. One-quarter had also undergone orthopaedic surgery. The most common pathogen was S. aureus, and most of the bone infections were chronic ( Table 1) .
Frequency of the tPA Alu (I/D) and PAI-1 (4G/5G) Polymorphisms in Osteomyelitis
The Yates' correction).
PAI-1/tPA Complex Levels and tPA Alu (I/D) and PAI-1 (4G/5G) Polymorphisms
Osteomyelitis patients who were II genotype carriers had lower PAI-1/tPA complex levels compared to those with the D allele of the tPA Alu (I/D) polymorphism (P ≤ .04; Figure 1 
Plasma Fibrinogen and D-Dimer and tPA Alu (I/D) and PAI-1 (4G/5G) Polymorphisms
There were no differences in plasma fibrinogen or D-Dimer levels between patients with the different genotypes of the tPA Alu (I/D) or PAI-1 (4G/5G); (data not shown).
DISCUSSION
We report for the first time an association between the tPA Alu (I/D) polymorphism and the development of osteomyelitis. The only other published association with this tPA polymorphism and a human infection is with periodontitis [17] . Other fibrinolysis-linked polymorphisms, mainly the PAI-1 (4G/5G), have been associated with different human infections. The PAI-1 (4G/5G) polymorphism was associated with an increased risk of developing bacterial pneumonia and a poorer outcome of meningococcal meningitis, with worse septic shock and disseminated intravascular coagulation [2, 4, 11, 12] . The 4G/4G carriers of the PAI-1 (4G/5G) polymorphism have been also associated with primary osteonecrosis presumably due to hypofibrinolysis, but no bone disease has been associated with the tPA Alu (I/D) polymorphism so far [23] .
The tPA-1 Alu (I/D) polymorphism has been associated with an increased "in vivo" release of tPA from forearm vascular endothelial cells. II tPA Alu (I/D) carriers have a significantly higher tPA release in comparison with ID and DD carriers [5] . Paradoxically, increased plasma tPA indicates inhibited endogenous fibrinolysis. This is because free tPA released into blood from endothelial cells immediately forms a complex with circulating PAI-1. Thus, assays of tPA antigen measure mainly inactive PAI-1/tPA complexes. Concentration of the PAI-1/ tPA complex levels in plasma correlated strongly with levels of tPA antigen and PAI-1activity [24] [25] [26] . In our study, osteomyelitis patients with the II genotype had significantly lower plasma PAI-1/tPA complex levels compared to those with other tPA Alu (I/D) genotypes and probably more circulating free tPA in plasma. Recently, an interaction between triosephosphate isomerase (TPI), an adhesion molecule displayed on the cell surface of S. aureus and plasminogen has been reported [27] . This interaction might enhance the adhesion of S. aureus to traumatized bone, thus increasing the likelihood of infection in carriers of the II genotype of the tPA Alu (I/D) polymorphism that have an activated fibrinolysis. However, no association between S. aureus osteomyelitis and the II genotype of the tPA Alu (I/D) polymorphism was observed in our study. The plasminogen-activating system relies on plasminogen activators that are serine proteases. They activate the conversion of the inactive proenzyme plasminogen into the active enzyme, plasmin. Plasmin could participate in bone and other tissue destruction by itself, degrading various components of the extracellular matrix proteins. In addition, plasminogen is chemotactic for PMN that might migrate to the site of bone infection and release extracellular matrix metaloproteases (MMPs) there. Thus, the fibrinolytic system alone or combined with activated MMPs could contribute to bone tissue destruction in association with cytokines and other inflammatory mediators [28] . This bone destruction might contribute to the pathogenesis of chronic osteomyelitis. We have reported previously the role of interleukin 1α (IL-1α) and MMP-1 SNPs, which increase plasma levels and bone expression of IL-1α and MMP-1, in increasing the susceptibility to develop osteomyelitis [19, 20] .
This plausible and novel hypothesis is supported by the fact that plasma PAI-1/tPA levels were lower in osteomyelitis patients who were carriers of the tPA Alu (I/D) polymorphism in our study. Because less tPA is inhibited and complexed by PAI, more free tPA must be present in the circulation activating the fibrinolisis. The profibrinolitic effect of the tPA Alu (I/D) polymorphism might be potentiated by the lower frequency of the 4G/4G genotype of the PAI-1 (4G/5G) polymorphism, a procoagulant genotype associated with higher PAI-1 plasma levels [28] . In fact, we could demonstrate among our osteomyelitis patients a more frequent presence of the II genotype of the tPA Alu (I/D) polymorphism associated with the 4G/5G and 5G/5G genotypes of the PAI-1 (4G/5G) polymorphism when compared with the controls. The 5G allele of the PAI-1 (4G/ 5G) polymorphism results in less transcription of PAI-1 because it binds a repressor protein and is associated with lower PAI-1 concentrations [13, 29] . Carriers of the 5G allele of the PAI-1 (4G/5G) polymorphism in our study probably had less free circulating PAI because they had less PAI-1/tPA complex formed. Interestingly, no differences in plasma fibrinogen or D-Dimer were observed among osteomyelitis patients carriers of the different genotypes of the tPA Alu (I/D) or PAI-1 (4G/5G) polymorphisms. Our results agree with those observed by Ten Boekel et al [30] in hospital patients with normal activated partial thromboplastin time (aPTT).
There is another plausible hypothesis to explain the osteomyelitis enhancing effect of the tPA Alu (I/D) polymorphism. Alu repeats increase local recombinant rates and perhaps the tPA Alu (I/D) polymorphism might be in linkage disequilibrium with an unidentified SNP in a coding region of the tPA gene [31] .
The adequate selection of control populations is critical in a study of genetic variants in any disease process. There is a broad variation in the carriage of the tPA Alu (I/D) polymorphism in different populations [32] .The observed allelic frequency of this polymorphism in our control population made of white healthy blood donors was very similar to that describe among Roman Jewish, Chinese, Cambodian, and West African populations, and close to that reported among Germans, Malaysians, and Indians but differed of the frequencies observed in Turkish and Swedish control populations [11, 17, [33] [34] [35] .
In summary, we describe here a potential association between the fibrinolytic system and osteomyelitis. More research is needed to confirm this observation and to improve the present scant knowledge on osteomyelitis pathogenesis.
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